Search

To ensure the high-reliability operation of overhead contact lines (OCLs), this paper proposes a data-driven time dependent reliability prediction approach, incorporating the maintenance factor, common cause failure (CCF), and lightning strike into reliability modeling and prediction for multi-component OCLs. Firstly, a new lightning-related failure probability calculation method is developed, including probabilistic lightning modeling, lightning identification, tracking and association analysis (LITAA), lightning movement trajectory prediction, and electric geometric model-based failure rate calculation. Moreover, a Bayesian network-based reliability model is embedded to integrate historical maintenance information, predictive lightning-related failure rate and fault tree model into reliability assessment of OCLs, which effectively captures the dependencies between failure events and depicts the impact of CCF on OCL components. In this context, the reliability of OCL components and OCLs can be predicted, with update of lightning strike data. Finally, the actual maintenance and lightning-related failure records are implemented to validate the effectiveness of the proposed approach. The result analysis demonstrates that our approach can not only illustrate how the reliability can be predicted using the predictive lightning-related failure rate, simultaneously accounting for imperfect maintenance and CCF, but also enhance risk prevention against lightning strike and faulty OCL components.

To enhance the affinity of the human epidermal growth receptor 2 (HER2) targeted peptide developed previously, bispecific fusion peptides P1GCGT1and P1GCGCGT1were designed using an in silicoapproach. Molecular dynamic simulation showed that both peptides strongly interacted with HER2 domains II and IV. Compared with peptides targeting each single domain, P1GCGT1and P1GCGCGT1could bind to HER2 more significantly and targeted HER2-positive cells specifically. Additionally, both peptides were used to generate peptide–drug conjugates with camptothecin (CPT), among which I-1and I-4were screened for enhanced cellular activity and selectivity. Biological evaluation demonstrated that I-1and I-4induced cell apoptosis, promoted cell cycle arrestin S-phase, and inhibited Topo I activity. The binding affinity assay and confocal analysis revealed that I-1and I-4were effective at targeting HER2. Moreover, I-1and I-4showed better stability than single targeting peptide and presented enhanced antitumor activity and safety than CPT in tumor-bearing mice.